Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.
Why Is VEXAS Syndrome Often Fatal? Here’s an Answer
The still-mysterious immunologic syndrome known as VEXAS seems to include heightened risk of infection, said researchers who warned that their findings suggest that the condition
December 13, 2023